propranolol has been researched along with Acute Confusional Senile Dementia in 14 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although several reports suggest that intermediate to high doses of propranolol (80-160 and 200-600 mg/day) can effectively treat aggressive behavior in dementia, significant side effects can occur at these doses." | 7.69 | Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. ( Cotman, CW; Nielson, KA; Shankle, WR, 1995) |
| " The benefits with bedaquiline or Sirturo® are its ability to likely provide clinically relevant activity as part of multi-drug regimens against tuberculosis (TB) based on clinical data in multi-drug resistant tuberculosis (MDR TB) patients, who were defined as being at least resistant against the two major tuberculostatic medicines (isaoniazide and rifampicine)." | 4.90 | [Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market]. ( Monneret, C, 2014) |
| "Although several reports suggest that intermediate to high doses of propranolol (80-160 and 200-600 mg/day) can effectively treat aggressive behavior in dementia, significant side effects can occur at these doses." | 3.69 | Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. ( Cotman, CW; Nielson, KA; Shankle, WR, 1995) |
| "Due to the complex nature of Alzheimer's disease, multi-target-directed ligand approaches are one of the most promising strategies in the search for effective treatments." | 1.42 | Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. ( Bajda, M; Brus, B; Czerwińska, P; Filipek, B; Gobec, S; Malawska, B; Sałat, K; Więckowska, A; Więckowski, K, 2015) |
| "Propranolol, at a lower dose than that used as antihypertensive (5 mg/kg, 6 wk), attenuated cognitive impairments shown by Tg2576 mice aged 9 months in the novel object recognition and fear conditioning tests." | 1.39 | Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. ( Dobarro, M; Gerenu, G; Ramírez, MJ, 2013) |
| " Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity." | 1.33 | Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Więckowska, A | 2 |
| Więckowski, K | 2 |
| Bajda, M | 1 |
| Brus, B | 1 |
| Sałat, K | 1 |
| Czerwińska, P | 1 |
| Gobec, S | 3 |
| Filipek, B | 1 |
| Malawska, B | 2 |
| Kołaczkowski, M | 1 |
| Bucki, A | 1 |
| Godyń, J | 1 |
| Marcinkowska, M | 1 |
| Zaręba, P | 1 |
| Siwek, A | 1 |
| Kazek, G | 1 |
| Głuch-Lutwin, M | 1 |
| Mierzejewski, P | 1 |
| Bienkowski, P | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Knez, D | 2 |
| Wichur, T | 1 |
| D'Acunto, CW | 1 |
| Kaplánek, R | 1 |
| Gbelcová, H | 1 |
| Kejík, Z | 1 |
| Bříza, T | 1 |
| Vasina, L | 1 |
| Havlík, M | 1 |
| Ruml, T | 1 |
| Král, V | 1 |
| Coquelle, N | 1 |
| Pišlar, A | 1 |
| Žakelj, S | 1 |
| Jukič, M | 1 |
| Sova, M | 1 |
| Mravljak, J | 1 |
| Nachon, F | 1 |
| Brazzolotto, X | 1 |
| Kos, J | 1 |
| Colletier, JP | 1 |
| Zhang, L | 1 |
| Fang, Y | 1 |
| Cheng, X | 1 |
| Lian, Y | 1 |
| Xu, H | 1 |
| Zeng, Z | 1 |
| Zhu, H | 1 |
| Dobarro, M | 1 |
| Gerenu, G | 1 |
| Ramírez, MJ | 1 |
| Mehta, DC | 1 |
| Short, JL | 1 |
| Nicolazzo, JA | 1 |
| Monneret, C | 1 |
| Tian, M | 1 |
| Zhu, D | 1 |
| Xie, W | 1 |
| Shi, J | 1 |
| Saber, AJ | 1 |
| Cain, DP | 1 |
| Rosin, RA | 1 |
| Raskind, MA | 1 |
| Sulkowski, A | 1 |
| Shankle, WR | 1 |
| Nielson, KA | 1 |
| Cotman, CW | 1 |
| Risse, SC | 1 |
| Barnes, R | 1 |
2 reviews available for propranolol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market].
Topics: Adrenergic beta-Antagonists; Adult; Alzheimer Disease; Aminophenols; Aniline Compounds; Antitubercul | 2014 |
Pharmacologic treatment of agitation associated with dementia.
Topics: Affective Symptoms; Aged; Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; | 1986 |
12 other studies available for propranolol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Blood-Brain Barrie | 2015 |
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cataly | 2016 |
Metallomics for Alzheimer's disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cations; Cell Proliferation; Cell Survival; Chelating Agen | 2018 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Li | 2018 |
TRPML1 Participates in the Progression of Alzheimer's Disease by Regulating the PPARγ/AMPK/Mtor Signalling Pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Amyloid beta-Protein Precur | 2017 |
Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; | 2013 |
Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Tran | 2013 |
Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.
Topics: Alzheimer Disease; Angiotensin II; Animals; Brain; Cognition; Dose-Response Relationship, Drug; Enzy | 2012 |
Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists.
Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; Cog | 2003 |
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo | 2005 |
Marihuana "high":a model of senile dementia?
Topics: Aged; Alzheimer Disease; Brain; Cannabis; Cognition; Dementia; Humans; Models, Biological; Propranol | 1980 |
Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients.
Topics: Aged; Aggression; Alzheimer Disease; Dementia; Female; Humans; Male; Middle Aged; Propranolol; Psych | 1995 |